Summation Cancer immunotherapy consists of approaches that modify the host immune
system, and/or the utilization of components of the immune system, as cancer treatment …

Purpose: To assess the current status of in-vivo use of monoclonal antibodies for treating
cancer. Data Identification: Publications appearing between 1980 and 1988 were identified …

With the FDA approval of Rituximab in 1998 for the treatment of lymphoma, and
Trastuzumab in 1999 for the treatment of breast cancer, monoclonal antibodies were …

Background. For patients with locally or regionally advanced non-small-cell lung cancer
radiation is the standard treatment, but survival remains poor. We therefore conducted a …

Background: For many years, high-dose radiation therapy was the standard treatment for
patients with locally or regionally advanced non-small-cell lung cancer (NSCLC), despite a 5 …

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense
Gene-Modified Allogeneic Tumor Cell Vaccine Page 1 Phase II Study of Belagenpumatucel-L …

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models
often encounter significant delays before being tested in patients with cancer. While some of …

Abstract Between 1982 and 1986, 326 evaluable patients with acute myeloid leukemia
(AML) were randomized to receive cytarabine (Ara-C) at 200 mg/m2 (A200) or 100 mg/m2 …

A man was hospitalized on three occasions for symptoms of lead intoxication 20 to 25 years
after a gunshot wound that resulted in retention of a lead bullet in his hip joint. The potential …

A Phase Ia clinical trial was undertaken to evaluate and compare murine monoclonal
antibody KS1/4 and KS1/4-methotrexate immunoconjugate in patients with Stage IIIB or IV …